Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors.
Autoimmune diseases of the nervous system
Immunotherapy
Nervous system
Neurologic immune-related adverse event (n-irAE)
Oncology
Paraneoplastic syndromes
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
11 Mar 2024
11 Mar 2024
Historique:
received:
29
11
2023
accepted:
10
02
2024
revised:
09
02
2024
medline:
12
3
2024
pubmed:
12
3
2024
entrez:
12
3
2024
Statut:
aheadofprint
Résumé
The clinical spectrum of melanoma-associated neurological autoimmunity, whether melanoma-associated paraneoplastic neurological syndromes (PNS) or induced by immune checkpoint inhibitors (ICI), is not well characterized. We aim to describe the clinical spectrum of melanoma-associated neurological autoimmunity. A systematic review of the literature combined with patients from French databases of paraneoplastic neurological syndromes was conducted. All melanoma patients with a possible immune-mediated neurologic syndrome were included and classified according to whether they had previously been exposed to ICI (ICI-neurotoxicity) or not (ICI-naïve) at first neurological symptoms. Seventy ICI-naïve (literature: n = 61) and 241 ICI-neurotoxicity patients (literature: n = 180) were identified. Neuromuscular manifestations predominated in both groups, but peripheral neuropathies were more frequent in ICI-neurotoxicity patients (39.4% vs 21.4%, p = 0.005) whereas myositis was more frequent in ICI-naïve patients (42.9% vs 18.7%, p < 0.001). ICI-naïve patients had also more frequent central nervous system (CNS) involvement (35.7% vs 23.7%, p = 0.045), classical paraneoplastic syndrome (25.7% vs 5.8%, p < 0.001), and more frequently positive for anti-neuron antibodies (24/32, 75.0% vs 38/90, 42.2%, p = 0.001). Although more ICI-neurotoxicity patients died during the acute phase (22/202, 10.9% vs 1/51, 2.0%, p = 0.047), mostly myositis patients (14/22, 63.6%), mortality during follow-up was higher in ICI-naïve patients (58.5% vs 29.8%, p < 0.001). There was no significant difference in the frequency of life independence (mRS ≤ 2) in the surviving patients in both groups (95.5% vs 91.0%, p = 0.437). Melanoma-associated PNS appear remarkably rare. The clinical similarities observed in neurological autoimmunity between ICI-treated and ICI-naïve patients, characterized predominantly by demyelinating polyradiculoneuropathy and myositis, suggest a potential prior immunization against melanoma antigens contributing to ICI-related neurotoxicity.
Sections du résumé
BACKGROUND
BACKGROUND
The clinical spectrum of melanoma-associated neurological autoimmunity, whether melanoma-associated paraneoplastic neurological syndromes (PNS) or induced by immune checkpoint inhibitors (ICI), is not well characterized. We aim to describe the clinical spectrum of melanoma-associated neurological autoimmunity.
METHODS
METHODS
A systematic review of the literature combined with patients from French databases of paraneoplastic neurological syndromes was conducted. All melanoma patients with a possible immune-mediated neurologic syndrome were included and classified according to whether they had previously been exposed to ICI (ICI-neurotoxicity) or not (ICI-naïve) at first neurological symptoms.
RESULTS
RESULTS
Seventy ICI-naïve (literature: n = 61) and 241 ICI-neurotoxicity patients (literature: n = 180) were identified. Neuromuscular manifestations predominated in both groups, but peripheral neuropathies were more frequent in ICI-neurotoxicity patients (39.4% vs 21.4%, p = 0.005) whereas myositis was more frequent in ICI-naïve patients (42.9% vs 18.7%, p < 0.001). ICI-naïve patients had also more frequent central nervous system (CNS) involvement (35.7% vs 23.7%, p = 0.045), classical paraneoplastic syndrome (25.7% vs 5.8%, p < 0.001), and more frequently positive for anti-neuron antibodies (24/32, 75.0% vs 38/90, 42.2%, p = 0.001). Although more ICI-neurotoxicity patients died during the acute phase (22/202, 10.9% vs 1/51, 2.0%, p = 0.047), mostly myositis patients (14/22, 63.6%), mortality during follow-up was higher in ICI-naïve patients (58.5% vs 29.8%, p < 0.001). There was no significant difference in the frequency of life independence (mRS ≤ 2) in the surviving patients in both groups (95.5% vs 91.0%, p = 0.437).
CONCLUSIONS
CONCLUSIONS
Melanoma-associated PNS appear remarkably rare. The clinical similarities observed in neurological autoimmunity between ICI-treated and ICI-naïve patients, characterized predominantly by demyelinating polyradiculoneuropathy and myositis, suggest a potential prior immunization against melanoma antigens contributing to ICI-related neurotoxicity.
Identifiants
pubmed: 38467790
doi: 10.1007/s00415-024-12252-0
pii: 10.1007/s00415-024-12252-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0012
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Greenlee JE, Carlson NG, Abbatemarco JR et al (2022) Paraneoplastic and other autoimmune encephalitides: antineuronal antibodies, T lymphocytes, and questions of pathogenesis. Front Neurol 12:1–16. https://doi.org/10.3389/fneur.2021.744653
doi: 10.3389/fneur.2021.744653
Yeh I, Bastian BC (2021) Melanoma pathology: new approaches and classification. Br J Dermatol. https://doi.org/10.1111/bjd.20427
doi: 10.1111/bjd.20427
pubmed: 34060071
pmcid: 9292921
Elder DE, Bastian BC, Cree IA et al (2020) The 2018 World Health Organization classification of cutaneous, mucosal, and uveal melanoma detailed analysis of 9 distinct subtypes defined by their evolutionary pathway. Arch Pathol Lab Med 144:500–522. https://doi.org/10.5858/arpa.2019-0561-RA
doi: 10.5858/arpa.2019-0561-RA
pubmed: 32057276
Ko JS (2017) The immunology of melanoma. Clin Lab Med 37:449–471. https://doi.org/10.1016/j.cll.2017.06.001
doi: 10.1016/j.cll.2017.06.001
pubmed: 28802495
Koebel CM, Vermi W, Swann JB et al (2007) Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450:903–907. https://doi.org/10.1038/nature06309
doi: 10.1038/nature06309
pubmed: 18026089
Vesely MD, Kershaw MH, Schreiber RD et al (2011) Natural innate and adaptive immunity. Annu Rev Immunol 235–71:235–271
doi: 10.1146/annurev-immunol-031210-101324
Vilaseca A, Martínez-Sáez E, González V et al (2023) Teaching neuroimage: paraneoplastic cerebellar degeneration and antibodies to TRIM 9 and 67 secondary to melanoma. Neurology 101:e1652–e1653. https://doi.org/10.1212/WNL.0000000000207702
doi: 10.1212/WNL.0000000000207702
pubmed: 37580164
Bataller L, Sabater L, Saiz A et al (2004) Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol 56:575–579. https://doi.org/10.1002/ana.20238
doi: 10.1002/ana.20238
pubmed: 15389893
Dalmau J, Graus F (2022) Autoimmune encephalitis and related disorders of the nervous system, 1st ed. Cambridge University Press. https://doi.org/10.1017/9781108696722
doi: 10.1017/9781108696722
Antoine J-C, Camdessanche J-P (2004) Paraneoplastic peripheral neuropathies. Rev Neurol (Paris) 160:188–198. https://doi.org/10.1016/s0035-3787(04)70890-5
doi: 10.1016/s0035-3787(04)70890-5
pubmed: 15034476
Kloos L, Sillevis Smitt P, Ang CW et al (2003) Paraneoplastic ophthalmoplegia and subacute motor axonal neuropathy associated with anti-GQ1b antibodies in a patient with malignant melanoma. J Neurol Neurosurg Psychiatry 74:507–509. https://doi.org/10.1136/jnnp.74.4.507
doi: 10.1136/jnnp.74.4.507
pubmed: 12640075
pmcid: 1738398
Nicolae CD, Nicolae I (2013) Antibodies against GM1 gangliosides associated with metastatic melanoma. Acta Dermatovenerol Croat 21:86–92
pubmed: 24001415
Graus F, Vogrig A, Muñiz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflam 8:e1014–e1027. https://doi.org/10.1212/NXI.0000000000001014
doi: 10.1212/NXI.0000000000001014
Rosenfeld MR, Dalmau J (2018) Paraneoplastic neurologic syndromes. Neurol Clin 36:675–685. https://doi.org/10.1016/j.ncl.2018.04.015
doi: 10.1016/j.ncl.2018.04.015
pubmed: 30072076
Taliansky A, Furman O, Gadot M et al (2021) Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: a single center experience. Support Care Cancer 29:7563–7568. https://doi.org/10.1007/s00520-021-06331-5
doi: 10.1007/s00520-021-06331-5
pubmed: 34120259
pmcid: 8550117
Marini A, Bernardini A, Gigli GL et al (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754–766. https://doi.org/10.1212/WNL.0000000000011795
doi: 10.1212/WNL.0000000000011795
pubmed: 33653902
Pepys J, Stoff R, Ramon-Gonen R et al (2023) Incidence and outcome of neurologic immune-related adverse events associated with immune checkpoint inhibitors in patients with melanoma. Neurology. https://doi.org/10.1212/WNL.0000000000207632
doi: 10.1212/WNL.0000000000207632
pubmed: 37652699
Guidon AC, Burton LB, Chwalisz BK et al (2021) Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother cancer. https://doi.org/10.1136/jitc-2021-002890
doi: 10.1136/jitc-2021-002890
pubmed: 34544895
pmcid: 8454442
Wang M, Rajan SS, Jacob AP et al (2020) Retrospective collection of 90-day modified Rankin Scale is accurate. Clin Trials 17:637–643. https://doi.org/10.1177/1740774520942466
doi: 10.1177/1740774520942466
pubmed: 32755236
Graus F, Titulaer MJ, Balu R et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9
doi: 10.1016/S1474-4422(15)00401-9
pubmed: 26906964
pmcid: 5066574
Van den Bergh PYK, Hadden RDM, Bouche P et al (2010) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Periphe. Eur J Neurol 17:356–363. https://doi.org/10.1111/j.1468-1331.2009.02930.x
doi: 10.1111/j.1468-1331.2009.02930.x
pubmed: 20456730
Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27(Suppl):S21–S24. https://doi.org/10.1002/ana.410270707
doi: 10.1002/ana.410270707
pubmed: 2194422
Van den Bergh PYK, van Doorn PA, Hadden RDM et al (2021) European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force-Second revision. Eur J Neurol 28:3556–3583. https://doi.org/10.1111/ene.14959
doi: 10.1111/ene.14959
pubmed: 34327760
Huang J, Chan SC, Ko S et al (2023) Global incidence, mortality, risk factors and trends of melanoma: a systematic analysis of registries. Am J Clin Dermatol. https://doi.org/10.1007/s40257-023-00795-3
doi: 10.1007/s40257-023-00795-3
pubmed: 37296344
Filippi L, Bianconi F, Schillaci O, Angela Spanu BP (2022) The role and potential of 18 F-FDG PET/CT in malignant melanoma : prognostication, monitoring response to targeted. Diagnostics. https://doi.org/10.3390/diagnostics12040929
doi: 10.3390/diagnostics12040929
pubmed: 36292114
pmcid: 9601187
Moghadam-Kia S, Oddis CV, Ascherman DP, Aggarwal R (2020) Risk factors and cancer screening in myositis. Rheum Dis Clin North Am 46:565–576. https://doi.org/10.1016/j.rdc.2020.05.006
doi: 10.1016/j.rdc.2020.05.006
pubmed: 32631604
Rajabally YA, Attarian S (2018) Chronic inflammatory demyelinating polyneuropathy and malignancy: a systematic review. Muscle Nerve 57:875–883. https://doi.org/10.1002/mus.26028
doi: 10.1002/mus.26028
pubmed: 29194677
Villagrán-García M, Muñiz-Castrillo S, Ciano-Petersen NL et al (2023) Paraneoplastic neurological syndromes associated with renal or bladder cancer: case series and PRISMA-IPD systematic review. J Neurol 270:283–299. https://doi.org/10.1007/s00415-022-11356-9
doi: 10.1007/s00415-022-11356-9
pubmed: 36050418
Tsuchida T, Saxton RE, Morton DLIR (1989) Gangliosides of human melanoma. Cancer 63:1166–1174
doi: 10.1002/1097-0142(19890315)63:6<1166::AID-CNCR2820630621>3.0.CO;2-5
pubmed: 2917320
Weiss MD, Luciano CA, Dalakas MC, Quarles RH (1998) Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 51:1738–1741
doi: 10.1212/WNL.51.6.1738
pubmed: 9855537
Farina A, Birzu C, Elsensohn M et al (2023) Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity. Brain Commun. https://doi.org/10.1093/braincomms/fcad186
doi: 10.1093/braincomms/fcad186
pubmed: 37794924
pmcid: 10546956
Poujade L, Samaran Q, Mura F et al (2021) Melanoma-associated retinopathy during pembrolizumab treatment probably controlled by intravitreal injections of dexamethasone. Doc Ophthalmol 142:257–263. https://doi.org/10.1007/s10633-020-09795-8
doi: 10.1007/s10633-020-09795-8
pubmed: 32975694
Sechi E, Markovic SN, McKeon A et al (2020) Neurologic autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes. Neurology 95:e2442–e2452. https://doi.org/10.1212/WNL.0000000000010632
doi: 10.1212/WNL.0000000000010632
pubmed: 32796130
pmcid: 7682911
Elsheikh S, Gurney SP, Burdon MA (2020) Melanoma-associated retinopathy. Clin Exp Dermatol 45:147–152. https://doi.org/10.1111/ced.14095
doi: 10.1111/ced.14095
pubmed: 31742740
Bourke JM, O’Sullivan M, Khattak MA (2016) Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors). Med J Aust 205:418–424. https://doi.org/10.5694/mja16.00586
doi: 10.5694/mja16.00586
pubmed: 27809739
Castanares-Zapatero D, Verleye L, Devos C et al (2024) Survival of patients with unfavorable prognosis cutaneous melanoma with increased use of immunotherapy agents: a population-based study in Belgium. Int J Dermatol. https://doi.org/10.1111/ijd.17046
doi: 10.1111/ijd.17046
pubmed: 38297428